OliX and Lilly Enter Global Licensing Agreement for MASH and Other Cardiometabolic Indications
OliX and Eli Lilly announced a global licensing agreement, focusing on the development and commercialization of OliX’s ...
Fierce Biotech20h
Eli Lilly inks duo of deals, teaming with AdvanCell, OliX to push deeper into radiopharma, MASH
Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...
Eli Lilly enters global license agreement with OliX for OLX75016
OliX Pharmaceuticals announced a global licensing agreement with Eli Lilly (LLY). This collaboration focuses on the development and ...
Eli Lilly Seeks To Expand Into Cancer Radiopharma And Fatty Liver, With Two Global Deals
Eli Lilly And Co (NYSE:LLY) inked two strategic collaborations to expand radiopharmaceuticals and metabolic-associated ...
Le Lézard20h
Stretch Zone Sets Its Sights on a Transformative 2025: Poised for Expansion and Innovation
Stretch Zone, the nation's leader in practitioner-assisted stretching, is stepping confidently into 2025 with a focus on innovation, growth, and strategic investments. Following a strong 2024, the ...
Le Lézard20h
AdvanCell Enters Into Strategic Collaboration with Lilly to Advance Novel Targeted Alpha Therapies for the Treatment of Cancer
AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, today announced an expansion to the scope and breadth of its strategic collaboration with Eli Lilly ...
Endpoints News13h
Eli Lil­ly inks $630M deal for Phase 1 MASH can­di­date
Eli Lilly is betting up to $630 million on an experimental MASH treatment from a South Korean biotech. The pharma giant ...